NCT06196034 Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.
| NCT ID | NCT06196034 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2028-01-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-03-01 with a primary completion date of 2028-01-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is limited information on genetics associated with asthma in Chinese. An earlier meta-analysis found that ADAM33, FcεRIb, RANTES, TNF-a, ACE, b2-AR, IL-4R and IL-13 genes could be proposed as asthma susceptible genes in the Chinese population. However, given the limited number of studies, more data are required to validate these associations. Future research must address key issues such as the broad clinical variability of asthma and the underrepresentation of populations of non-European heritage. Endotype-specific SNPs and unique biological insights may be obtained by conducting GWAS/EWAS on homogeneous populations of more therapy-resistant T2-low, adult-onset, obesity-associated asthma or asthma with particular co-morbidities. The primary objective is to investigate the association between genetic polymorphisms and various severities of asthma.
Eligibility Criteria
Inclusion Criteria: * • All patients with confirmed diagnosis of asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 12 * Able to sign written informed consent form to participate in the study. Exclusion Criteria: * • Patients currently with acute exacerbation of asthma by GINA guideline. (For subjects with asthma exacerbation, they can join the study after 6 weeks post recovery from the exacerbation.) * Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis(TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment. * Patients currently diagnosed with pneumonia and acute bronchitis. For control subject: the inclusion will be having no clinical diagnosis of asthma.
Contact & Investigator
David SC Hui
STUDY DIRECTOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT06196034 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06196034 currently recruiting?
Yes, NCT06196034 is actively recruiting participants. Contact the research team at dschui@cuhk.edu.hk for enrollment information.
Where is the NCT06196034 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong.
Who is sponsoring the NCT06196034 clinical trial?
NCT06196034 is sponsored by Chinese University of Hong Kong. The principal investigator is David SC Hui at Chinese University of Hong Kong. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.